Omer Gilan
Omer Gilan
Peter MacCallum cancer centre
Verified email at petermac.org
Title
Cited by
Cited by
Year
BET inhibitor resistance emerges from leukaemia stem cells
CY Fong, O Gilan, EYN Lam, AF Rubin, S Ftouni, D Tyler, K Stanley, ...
Nature 525 (7570), 538-542, 2015
3682015
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
ML Burr, CE Sparbier, YC Chan, JC Williamson, K Woods, PA Beavis, ...
Nature 549 (7670), 101-105, 2017
3272017
Nuclease target site selection for maximizing on-target activity and minimizing off-target effects in genome editing
CM Lee, TJ Cradick, EJ Fine, G Bao
Molecular Therapy 24 (3), 475-487, 2016
142*2016
An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer
ML Burr, CE Sparbier, KL Chan, YC Chan, A Kersbergen, EYN Lam, ...
Cancer cell 36 (4), 385-401. e8, 2019
1332019
Multiplexed proteome dynamics profiling reveals mechanisms controlling protein homeostasis
MM Savitski, N Zinn, M Faelth-Savitski, D Poeckel, S Gade, I Becher, ...
Cell 173 (1), 260-274. e25, 2018
1182018
CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
GP Gregory, SJ Hogg, LM Kats, E Vidacs, AJ Baker, O Gilan, M Lefebure, ...
Leukemia 29 (6), 1437-1441, 2015
992015
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
O Gilan, I Rioja, K Knezevic, MJ Bell, MM Yeung, NR Harker, EYN Lam, ...
Science 368 (6489), 387-394, 2020
942020
Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
R Agarwal, YC Chan, CS Tam, T Hunter, D Vassiliadis, CE Teh, ...
Nature Medicine 25 (1), 119-129, 2019
832019
Functional interdependence of BRD4 and DOT1L in MLL leukemia
O Gilan, EYN Lam, I Becher, D Lugo, E Cannizzaro, G Joberty, A Ward, ...
Nature structural & molecular biology 23 (7), 673-681, 2016
802016
Click chemistry enables preclinical evaluation of targeted epigenetic therapies
DS Tyler, J Vappiani, T Cañeque, EYN Lam, A Ward, O Gilan, YC Chan, ...
Science 356 (6345), 1397-1401, 2017
782017
Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells
J Diesch, E Sanij, O Gilan, C Love, H Tran, NI Fleming, J Ellul, M Amalia, ...
PloS one 9 (3), e88950, 2014
662014
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
CC Bell, KA Fennell, YC Chan, F Rambow, MM Yeung, D Vassiliadis, ...
Nature communications 10 (1), 1-15, 2019
592019
Principles and mechanisms of non-genetic resistance in cancer
CC Bell, O Gilan
British journal of cancer 122 (4), 465-472, 2020
372020
Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2
SA Kinkel, R Galeev, C Flensburg, A Keniry, K Breslin, O Gilan, S Lee, ...
Blood, The Journal of the American Society of Hematology 125 (12), 1890-1900, 2015
352015
PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity
O Gilan, J Diesch, M Amalia, K Jastrzebski, AC Chueh, NM Verrills, ...
Oncogene 34 (10), 1333-1339, 2015
242015
A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells
JL Pakay, J Diesch, O Gilan, YY Yip, E Sayan, W Kolch, JM Mariadason, ...
Oncogene 31 (14), 1817-1824, 2012
242012
Id2 and E proteins orchestrate the initiation and maintenance of MLL-rearranged acute myeloid leukemia
M Ghisi, L Kats, F Masson, J Li, T Kratina, E Vidacs, O Gilan, MA Doyle, ...
Cancer Cell 30 (1), 59-74, 2016
202016
Regulation of perforin activation and pre‐synaptic toxicity through C‐terminal glycosylation
IG House, CM House, AJ Brennan, O Gilan, MA Dawson, JC Whisstock, ...
EMBO reports 18 (10), 1775-1785, 2017
192017
An Erg-driven transcriptional program controls B cell lymphopoiesis
AP Ng, HD Coughlan, S Hediyeh-Zadeh, K Behrens, TM Johanson, ...
Nature communications 11 (1), 1-14, 2020
82020
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
AC Watt, P Cejas, MJ DeCristo, O Metzger-Filho, EYN Lam, X Qiu, ...
Nature Cancer 2 (1), 34-48, 2021
52021
The system can't perform the operation now. Try again later.
Articles 1–20